Multi-vesicular liposome formulations of dexamethasone

Some embodiments of the present application are directed to multivesicular liposome (MVL) formulations that encapsulate dexamethasone, or an ester or ester salt thereof, such as dexamethasone sodium phosphate (DSP), that can provide extended release of dexamethasone of about 3 to 28 days. Methods of...

Full description

Saved in:
Bibliographic Details
Main Authors SIMONIAN ALYSSA R, GARCIA, LOUIS, D, DAVIS PAIGE N, GRIGSBY, JOHN, J., JR, LEVI, ILAN, LOS KATHLEEN D. A, LYON, DAMON, A, ADKANI, SOROS, M, KURZ STEPHANIE M
Format Patent
LanguageChinese
English
Published 07.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Some embodiments of the present application are directed to multivesicular liposome (MVL) formulations that encapsulate dexamethasone, or an ester or ester salt thereof, such as dexamethasone sodium phosphate (DSP), that can provide extended release of dexamethasone of about 3 to 28 days. Methods of making and administering dexamethasone encapsulated multivesicular liposome formulations and their use for the treatment of pain or inflammation are also provided. 本申请的一些实施方式涉及包封地塞米松或其酯或酯盐例如地塞米松磷酸钠(DSP)的多囊脂质体(MVL)制剂,其可以提供约3至28天的地塞米松延长释放。还提供了地塞米松包封多囊脂质体制剂的制造和施用方法及其用于治疗疼痛或炎症的用途。
Bibliography:Application Number: CN202280064031